Considering the positive correlation between PN and efficacy outcomes, the identification of risk factors for CINP and its management becomes critical; indeed, as demonstrated for other drugs (e.g., Tyrosine Kinase Inhibitor, Anti-Epidermal Growth Factor Receptors), the occurrence of adverse events such as hypertension or skin rash could be used as a surrogate of efficacy [52,53]. This evidence concerns the gene EGFR and Hypertension.